Amicus Therapeutics, Inc. $FOLD Shares Acquired by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 24.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 3,434,717 shares of the biopharmaceutical company’s stock after acquiring an additional 674,403 shares during the quarter. Amicus Therapeutics comprises approximately 1.5% of Rice Hall James & Associates LLC’s holdings, making the stock its 19th largest position. Rice Hall James & Associates LLC owned approximately 1.11% of Amicus Therapeutics worth $27,066,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Osaic Holdings Inc. lifted its stake in Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Amicus Therapeutics by 472.6% during the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,677 shares during the last quarter. Strs Ohio bought a new stake in shares of Amicus Therapeutics in the 1st quarter valued at approximately $30,000. CWM LLC grew its position in Amicus Therapeutics by 395.9% in the second quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 7,502 shares in the last quarter. Finally, Inceptionr LLC acquired a new position in Amicus Therapeutics during the second quarter worth $61,000.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 77,926 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $10.86, for a total transaction of $846,276.36. Following the completion of the sale, the chief executive officer owned 1,129,782 shares in the company, valued at $12,269,432.52. This trade represents a 6.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ellen Rosenberg sold 36,000 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.00, for a total transaction of $360,000.00. Following the completion of the transaction, the insider owned 507,710 shares in the company, valued at approximately $5,077,100. This trade represents a 6.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 345,450 shares of company stock valued at $3,657,000 in the last ninety days. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $14.25 on Friday. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70. The company has a 50-day moving average price of $10.08 and a two-hundred day moving average price of $8.11. The stock has a market cap of $4.40 billion, a price-to-earnings ratio of -356.16 and a beta of 0.46. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $14.36.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. The business had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.Amicus Therapeutics’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. Equities analysts predict that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on FOLD shares. Needham & Company LLC cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. JPMorgan Chase & Co. boosted their price target on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Cantor Fitzgerald cut Amicus Therapeutics from an “overweight” rating to a “hold” rating and cut their price target for the company from $21.00 to $14.50 in a report on Friday, December 19th. The Goldman Sachs Group lifted their price objective on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $15.81.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.